SCHEMBL16396513

SCHEMBL16396513

COC(=O)Cc1ccccc1NC(=O)c1ccc(OC)c(-c2cc(F)cc(CN)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 6/20 0.61
▸ SUCNR1 Q9BXA5 3/20 0.47
▸ F11 P03951 1/20 0.47
▸ TPSB2 P20231 1/20 0.47
▸ ROCK2 O75116 2/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ PDE4D Q08499 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ MAPK8 P45983 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CD274 Q9NZQ7 1/20 0.39
▸ ABCB1 P08183 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16410278 0.93 SUCNR1 (0.56) CFDSUCNR1F11TPSB2KMT2A
SCHEMBL16396533 0.88 CFD (0.76) CFDSUCNR1F11TPSB2ROCK2
SCHEMBL16397756 0.80 CFD (0.71) CFDSUCNR1F11TPSB2
SCHEMBL16396802 0.79 CFD (0.60) CFDSUCNR1F11TPSB2ROCK2
SCHEMBL16396465 0.76 CFD (1.00) CFDSUCNR1F11TPSB2ROCK2
SCHEMBL16396385 0.75 CFD (0.76) CFDSUCNR1F11TPSB2ROCK2
SCHEMBL16397037 0.74 CFD (0.52) CFDSUCNR1F11TPSB2
SCHEMBL16410319 0.74 SUCNR1 (0.80) CFDSUCNR1F11TPSB2
SCHEMBL16410363 0.73 CFD (0.52) CFDSUCNR1F11TPSB2LMNA
SCHEMBL16403609 0.72 SUCNR1 (0.56) CFDSUCNR1F11TPSB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885SUCNR1 4670/4885F11 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback